How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,892 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness

Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Published on: September 25, 2017 Project (...) Number: RC0930-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of genital warts? What is the cost-effectiveness of imiquimod for the treatment of genital warts? Key Message Evidence from systematic reviews with low quality included studies suggests that overall for patients with anogenital warts (AGW) compared to placebo, treatment with imiquimod (IMQ) is associated

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness

Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Published on: September 15, 2017 Project Number: RC0929-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of actinic keratosis? What is the cost-effectiveness of imiquimod for the treatment of actinic keratosis? Key Message The three included systematic reviews showed that in patients with actinic keratosis (AK), treatment with imiquimod (IMQ) appeared to be better than placebo with respect to complete clearance.Few primary studies were available

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN)

Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN) To compare the recurrence rates after complete response to topical treatment with either cidofovir or imiquimod for vulval intraepithelial neoplasia (VIN) 3.A prospective, open, randomised multicentre trial.32 general hospitals located in Wales and England.180 patients were randomised consecutively between 21 October 2009 and 11 January (...) 2013, 89 to cidofoovir (of whom 41 completely responded to treatment) and 91 to imiquimod (of whom 42 completely responded to treatment).After 24 weeks of treatment, complete responders were followed up at 6-monthly intervals for 24 months. At each visit, the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was assessed and any new lesions were biopsied for histology.Time to histologically confirmed disease recurrence (any grade of VIN).The median length of follow up was 18.4 months

Full Text available with Trip Pro

2018 EvidenceUpdates

4. Recurrence of lentigo maligna and melanoma in situ after topical treatment with 5% imiquimod: a meta-analysis

Recurrence of lentigo maligna and melanoma in situ after topical treatment with 5% imiquimod: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

5. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. (PubMed)

Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. The pathology of psoriasis strongly depends on IL-17A. Monoclonal antibodies blocking either the cytokine or its receptor are among the most efficient treatments for psoriatic patients. Keratinocytes can be activated upon exposure to IL-17A and tumor necrosis factor-α and secrete secondary cytokines and chemokines in the inflamed skin. In psoriasis and its imiquimod-induced mouse model, a strong skin (...) development. Only deletion of this receptor in keratinocytes reflected the full-body deletion of IL-17RA, resulting in strongly reduced dermatitis development. Imiquimod treatment of those IL-17 signaling-deficient mice maintained high monocytic infiltration but failed to attract neutrophils into the skin. We conclude that keratinocytes are a critical cellular target for IL-17A-mediated neutrophil attraction and psoriasis development.Copyright © 2019 The Authors. Published by Elsevier Inc. All rights

2019 Journal of Investigative Dermatology

6. Impact of smoking on imiquimod response in patients with vulval intraepithelial neoplasia. (PubMed)

Impact of smoking on imiquimod response in patients with vulval intraepithelial neoplasia. Vulval intraepithelial neoplasia (VIN) is a precancerous condition that may progress to invasive malignancy. VIN is associated with human papillomavirus (HPV) infection in most cases, and with inflammatory skin disorders in a smaller proportion of patients. Treatment of VIN has traditionally been surgical excision; however, topical treatments, including imiquimod cream, are becoming increasingly used (...) . Patient factors influencing response to imiquimod therapy, in particular smoking, have not yet been published.To assess the impact of smoking and other patient characteristics that may influence the treatment response to topical imiquimod for VIN.This was a retrospective cohort study of 46 women treated with topical imiquimod for VIN in a single centre dermatology unit from January 2011 to July 2017.Complete clinical resolution of VIN was observed in 28 of 46 patients (61%), but was significantly

2019 Clinical & Experimental Dermatology

7. Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. (PubMed)

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory (...) cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C

2019 Journal of biophotonics

8. Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. (PubMed)

Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. [This corrects the article DOI: 10.1371/journal.pone.0176823.].

Full Text available with Trip Pro

2018 PLoS ONE

9. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. (PubMed)

Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. Imiquimod 3.75% is a field-directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun-exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (Lmax ). We report clinical outcomes for the first 15 patients treated with imiquimod 3.75 (...) % in daily clinical practice in Greece.Fifteen patients with actinic keratosis lesions were treated with imiquimod 3.75% in an outpatient setting in two 2-week treatment cycles separated by a 2-week treatment-free interval. Actinic keratosis lesions were counted before treatment, at the end of the first treatment cycle (Week 2; Lmax ), and 2 weeks after the second treatment cycle (Week 8). Local skin reactions (LSR) were also evaluated at Weeks 2 and 8.The median baseline actinic keratosis lesion count

2019 International Journal of Dermatology

10. Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. (PubMed)

Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. Actinic keratoses (AK) represent common cutaneous lesions, appearing in "Field cancerization areas" and potentially evolving towards invasive neoplasm. Immunosuppressed patients frequently develop numerous and aggressive AKs.In this observational study, we report our experience with topical Imiquimod 3.75% as "Field-directed therapy" in a cohort (...) of immunosuppressed patients.A group of 13 immunosuppressed patients presenting multiple AKs of the balding scalp was treated with topical Imiquimod 3.75%. Each patient underwent clinical examination at fixed timepoints during the treatment (T0, T14, T28, T42) and eight weeks after the end.In our cohort, the treatment was well tolerated, with minimal local adverse events. We observed a good clinical response, in terms of Lmax lesions (maximum lesion count during the course of therapy) and of AK clearance. In our

2019 Journal of Dermatological Treatment

11. Long-term outcomes of imiquimod-treated lentigo maligna. (PubMed)

Long-term outcomes of imiquimod-treated lentigo maligna. Lentigo maligna (LM) may be disfiguring and can progress to LM melanoma. Surgical excision remains the mainstay of treatment, but may result in disfigurement when used for large facial lesions. Topical imiquimod is a nonsurgical alternative although data on its long-term efficacy remain limited.To assess long-term outcomes of LM treated with imiquimod cream.We collected data retrospectively for 33 patients treated with imiquimod cream (...) for biopsy-proven LM from 2001 to 2016. Patients initially applied imiquimod once daily, 5 days/week for 6 weeks, aiming to produce a brisk local inflammatory response. If there was no response, the dose was increased to twice daily 7 days/week for 6 weeks and if again there was no response, to twice daily for 10 weeks.An inflammatory response developed in 29 (88%) of the 33 patients, and of these, 4 patients stopped treatment earlier than planned because they could not tolerate the inflammatory reaction

2019 Clinical & Experimental Dermatology

12. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. (PubMed)

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard but an alternative treatment is off-label topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treatment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete (...) clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo maligna melanoma which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients

Full Text available with Trip Pro

2019 Acta Dermato-Venereologica

13. Imiquimod-induced skin inflammation is relieved by knockdown of sodium channel Na<sub>x</sub>. (PubMed)

Imiquimod-induced skin inflammation is relieved by knockdown of sodium channel Nax. Nax is an atypical sodium channel that mediates inflammatory pathways in pathological conditions of the skin. In this study, we developed a skin inflammation model in the rabbit ear through application of imiquimod (IMQ). Knockdown of Nax using RNAi attenuated IMQ-induced skin inflammation, including skin erythema, scaling, and papule formation. Histologic analysis showed that thickening

2019 Experimental Dermatology

14. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. (PubMed)

Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. Psoriasis is a chronic inflammatory skin disease. Anti-TNFα, IL-17A and IL-23p19 antibodies are effective for psoriasis. However, the contribution of regulatory T cells (Treg) in their effectiveness remains to be elucidated.We investigated the effects of TNFα, IL-17A and IL-23p19 inhibition on Tregs (...) in imiquimod-induced psoriasiform dermatitis.Psoriasiform dermatitis was induced by imiquimod application on murine shaved back skin for six days. Mice were treated with anti-TNFα, IL-17A or IL-23p19 monoclonal antibodies every other day from one day before imiquimod application.Administration of anti-TNFα, IL-17A or IL-23p19 antibodies improved the clinical score and downregulated Th17-related cytokines and chemokines, while IL-23p19 antibodies upregulated IL-10 mRNA expression. Anti-IL-17A or IL-23p19

2019 Journal of dermatological science

15. "Imiquimod acts synergistically with BMP9 via the Notch pathway as an osteoinductive agent in vitro". (PubMed)

"Imiquimod acts synergistically with BMP9 via the Notch pathway as an osteoinductive agent in vitro". Autologous bone grafts used for surgical reconstruction are limited by infection or insufficient supply of host material. Experimental agents that promote differentiation of stem cells into mature bone are currently being studied for future use in the repair of bone defects. We hypothesized that Imiquimod, a synthetic immune response modifier, increases Notch pathway gene expression and acts (...) synergistically with BMP9 to induce differentiation of mesenchymal stem cells (MSCs) toward an osteogenic phenotype.Alkaline phosphatase (ALP) activity was used to assess osteogenic potential of cultured mouse multipotent adipose-derived cells (iMADs) treated with 0, 4, 6, and 8 ∞g/mL of Imiquimod with and without BMP9. Adenoviral vectors expressing human-BMP9 and a dominant-negative mutant of mouse Notch1 were used to assess BMP9 and Notch blockade, on osteogenic activity, respectively. Expression of Notch

2019 Plastic and reconstructive surgery

16. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. (PubMed)

Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. Actinic keratosis (AK) is an early in situ epidermal cancer which can progress to invasive squamous cell carcinoma (SCC). Imiquimod 5% cream (IMIQ) and diclofenac 3% gel (DIC) are frequently used to treat AK; however, their long-term effects following repeated treatment cycles have never been compared.To compare IMIQ and DIC

2019 Journal of the European Academy of Dermatology and Venereology

17. A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response. (PubMed)

A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response. Lentigo Maligna (LM) is a common subtype of in-situ melanoma on chronically sun-exposed skin, particularly the head and neck of older patients. Whilst surgery is the standard treatment, there is associated morbidity and options such as imiquimod cream or radiotherapy may be used if surgery is refused or inappropriate. Complete response rates following imiquimod treatment are variable (...) in the literature. The aim of this study was to evaluate the host immune response both prior to and following treatment with imiquimod to better identify likely responders. Paired pre- and post-imiquimod treatment specimens were available for 27 patients. Patients were treated with imiquimod 5 days per week for 12 weeks; at 16 weeks, lesions were excised for histological assessment. 16 of the 27 patients were responders and 11 failed to clear the disease. PDL1 protein expression was increased, accompanied

2019 Journal of Investigative Dermatology

18. Imiquimod to prevent keloid recurrence post excision: A systematic review and meta-analysis. (PubMed)

Imiquimod to prevent keloid recurrence post excision: A systematic review and meta-analysis. Imiquimod 5% cream, an immune response modifier capable of inducing IFN-α, TNF-α and interleukins 1, 6 and 8. It was approved for use in the management of genital and perianal warts and soon embraced as a method to diminish the recurrence of keloids post excision. A previous meta-analysis included four studies. This meta-analysis is part of a larger systematic review project on the effect (...) of 39% (95% CI = 8.4% to 74.4%; I2 =87.5%) following application of Imiquimod post excision. The use of primary excision or tangential excision did not alter the outcome. For analysis based on the location of the keloid scar, earlobe keloids had a recurrence rate of 5.4% (95% CI=0% to 21.7%; I2 =52.9 %). For keloids excised from other areas (predominantly on the trunk) recurrence rate was higher, at 76.8% (95% CI = 36.1% to 100%). For keloids, Imiquimod application post excision results in highly

2019 Wound Repair and Regeneration

19. Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial. (PubMed)

Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial. Background: We conducted this meta-analysis to compare the efficacy and safety of imiquimod with other treatments in patients with basal cell carcinoma (BCC). Methods: A comprehensive literature search was performed in the database of PubMed, Embase, and Web of Science, focusing on studies that evaluated the efficacy and safety profile of BCC patients who were treated (...) with imiquimod. The main outcome measures included histological/composite clearance rate, success rate, complete response rate, tumor free survival, and adverse events. Results were expressed as risk ratio (RR) with 95% confidence intervals (CIs). Pooled estimates were calculated using a fixed-effects or random-effects model according to the heterogeneity among studies. Results: A total of 13 studies involving 4256 patients were included in this meta-analysis. Imiquimod was associated with significantly

2019 Journal of Dermatological Treatment

20. Acupuncture Needling, Electroacupuncture, and Fire Needling Improve Imiquimod-Induced Psoriasis-Like Skin Lesions through Reducing Local Inflammatory Responses. (PubMed)

Acupuncture Needling, Electroacupuncture, and Fire Needling Improve Imiquimod-Induced Psoriasis-Like Skin Lesions through Reducing Local Inflammatory Responses. Psoriasis is a common autoimmune disease. Acupuncture-related techniques have been widely used to treat psoriasis since its ability to engage neuronal function, the immune system, and other systems is well documented. This study aimed to investigate and compare the effects of three common acupuncture-related techniques in psoriasis-like (...) skin inflammatory responses and explore the possible involved mechanisms. Imiquimod (IMQ)-induced psoriasis-like mice were treated with acupuncture needling, electroacupuncture, or fire acupuncture. Methotrexate (MTX) was applied as a positive control. Scoring by the psoriasis area and severity index (PASI) evaluated skin lesion changes. Keratinocyte proliferation and inflammatory cell infiltration were investigated using pathological staining. The secretion levels of inflammatory cytokines were

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>